COMPANY

Orlucent

HQ: Los Gatos, CA source · orlucent.com ↗ · West Coast

Location: Los Gatos, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Keywords: Skin Lesion Nevus Dysplastic Nevi Melanoma (Skin) Mole Melanoma Moles

Funding and NIH signals

NIH award NIH awarded $1.56M (SBIR Phase II 1R44CA306680-01A1, new, notice Sep 3, 2026). NIH RePORTER 1R44CA306680-01A1 (Sep 3, 2026)
Evidence (1 event)
- Sep 3, 2026 · NIH RePORTER 1R44CA306680-01A1
  Organization: ORLUCENT, INC.; City/State: Los Gatos, CA; Project number: 1R44CA306680-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 1556529; Administering IC: National Cancer Institute; Project title: Development of Manufacturing Controls for ORL1: A Fluorescent Imaging Agent for In Vivo Molecular Imaging of Melanomas; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Jun 15, 2023 Trial start —: INTER-PATHOLOGIST READER STUDY source ↗
Aug 10, 2020 Trial start —: Skin Fluorescent Imaging (SFI) System in Patients With Nevi source ↗
Apr 1, 2018 Trial start —: Investigating the Clinical Utility of the MDS source ↗
Jan 24, 2018 Trial start —: Assessing Tissue Remodeling in the Skin Using SFI (Skin Fluorescence Imaging) source ↗
Aug 30, 2017 Trial start —: Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging source ↗
2016-07 Trial start —: Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging source ↗
2013-06 Trial start —: Pilot Study to Determine Feasibility of Benign and Malignant Skin Lesion Detection. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT04368247	Skin Fluorescent Imaging (SFI) System in Patients With Nevi	Not listed	Completed	Aug 10, 2020	Jun 30, 2023 (actual)
NCT06246903	INTER-PATHOLOGIST READER STUDY	Not listed	Unknown status (ClinicalTrials.gov)	Jun 15, 2023	Jun 20, 2024 (estimated)
NCT03535077	Assessing Tissue Remodeling in the Skin Using SFI (Skin Fluorescence Imaging)	Not listed	Completed	Jan 24, 2018	Dec 31, 2022 (actual)
NCT03109327	Investigating the Clinical Utility of the MDS	Not listed	Completed	Apr 1, 2018	Oct 30, 2020 (actual)
NCT02056522	Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging	Not listed	Completed	2016-07	2018-04 (actual)
NCT02193581	Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging	Not listed	Completed	Aug 30, 2017	Dec 1, 2017 (actual)
NCT02009085	Pilot Study to Determine Feasibility of Benign and Malignant Skin Lesion Detection.	Not listed	Completed	2013-06	2017-06 (actual)

Annual award amounts. Total $1.6M.

Sep 3, 2026 NIH award 1R44CA306680-01A1 FY2026: $1,556,529 awarded for that fiscal year; activity R44 (SBIR); PI SHACHAF, CATHERINE; recipient as written: ORLUCENT, INC., Los Gatos, CA. Development of Manufacturing Controls for source ↗